<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125757</url>
  </required_header>
  <id_info>
    <org_study_id>P.T.REC/012/003344</org_study_id>
    <nct_id>NCT05125757</nct_id>
  </id_info>
  <brief_title>Lifestyle Modification in Psoriatic Patients With Fatty Liver</brief_title>
  <official_title>Response of Fatty Liver to Lifestyle Modification in Psoriasis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several recent reports have shown an increased prevalence of nonalcoholic fatty liver disease&#xD;
      (NAFLD) in those with psoriasis, which may reflect the increased occurrence of metabolic&#xD;
      syndrome in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the recruitment of 60 fatty live men with chronic disease, psoriasis, will be classified to&#xD;
      lifestyle modification group (foe 12 weeks, this patients will take supervised energy or diet&#xD;
      restriction program plus their usual immunosuppressive drugs ) and control group will&#xD;
      continue their drug program only)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index</measure>
    <time_frame>It will be measured after 12 weeks</time_frame>
    <description>it is an index used to measure level and severity of psoriasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index</measure>
    <time_frame>It will be measured after 12 weeks</time_frame>
    <description>it is a questinnaire used to assess life quality in psoriasis humans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglycerides</measure>
    <time_frame>It will be measured after 12 weeks</time_frame>
    <description>will measured in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>It will be measured after 12 weeks</time_frame>
    <description>it is plasma aspartate transaminase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>It will be measured after 12 weeks</time_frame>
    <description>it is plasma Alanine transaminase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>It will be measured after 12 weeks</time_frame>
    <description>it is body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>It will be measured after 12 weeks</time_frame>
    <description>it will be measured at the level of umbilicus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Psoriasis</condition>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants of this group will receive their usual immuno-modulating therapy and continuing their usual diet and activities</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lifestyle modification</intervention_name>
    <description>for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>usual lifestyle</intervention_name>
    <description>the patients will receive the usual immuno-modulating therapy with continued usual diet and activities</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  psoriasis obese patients with coexisting fatty liver&#xD;
&#xD;
          -  chronic plaque psoriasis&#xD;
&#xD;
          -  patients who will not show any change in immuno-modulating psoriasis therapies for at&#xD;
             least five months before participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no metabolic syndrome&#xD;
&#xD;
          -  no renal or cardiac or pulmonary disorders&#xD;
&#xD;
          -  other types of psoriasis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>self-representation of gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Ismail, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali Ismail, lecturer</last_name>
    <phone>02 01005154209</phone>
    <email>allooka2012@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Physical Therapy Cairo University</name>
      <address>
        <city>Giza</city>
        <state>Dokki</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Ismail, lecturer</last_name>
      <phone>02 01005154209</phone>
      <email>allooka2012@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ali Mohamed Ali ismail</investigator_full_name>
    <investigator_title>lecturer of Physical Therapy for Cardiovascular / Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

